Sun Pharmaceutical Industries
null
position
long
William Strong
Thesis
Sun Pharma is growing at 15-25% per year and generating net cash while doing so, making it a compelling business in an environment where reinvestment can yield high returns.
Did it work?
inconclusive
confidence: low
Without specific price performance data or a defined time frame since the pitch, it's difficult to assess whether the thesis has played out. While the growth rate of 15-25% and net cash generation are positive indicators, the lack of concrete results or time elapsed prevents a definitive judgment.
Raw excerpt
No raw excerpt stored.